Dasatinib 100 MG

DRUG4 trials

Sponsors

Bristol-Myers Squibb, Nanfang Hospital, Southern Medical University, Cedars-Sinai Medical Center, Centro de Atencion e Investigacion Medica

Conditions

Breast CancerHealthy LifestyleMetastasisMyeloma MultipleObesityValidity and Safety

Phase 2

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

CompletedNCT00371345

Bristol-Myers SquibbBreast Cancer, Metastasis

Start: 2006-12-31End: 2009-05-31Updated: 2011-04-26

Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects

RecruitingNCT05653258

Cedars-Sinai Medical CenterHealthy Lifestyle, Obesity

Start: 2023-10-17End: 2028-02-01Target: 160Updated: 2026-03-18

Phase 4

Bioequivalence Studies of Dasatinib 100 Mg

Not yet recruitingNCT05944783

Centro de Atencion e Investigacion MedicaMyeloma Multiple

Start: 2025-09-01End: 2026-04-30Target: 46Updated: 2025-02-12

Unknown Phase

Early Conversion of Dasatinib in CML-CP Patients

Nanfang Hospital, Southern Medical UniversityValidity and Safety

Start: 2019-10-22End: 2021-12-31Target: 200Updated: 2020-12-10